fluoxymesterone (Haloestin, Ora-Testryl)

Introduction

Tradenames: Haloestin, Ora-Testryl. DEA controlled substance. Class 3.

Indications

• males:
  • androgen deficiency
    • replacement therapy in hypogonadism & delayed puberty
  • orchitis
  • scrotal pain/mass
  • cryptorchidism
  • Klinfelter's syndrome
  • anorchia
• females:
  • metastatic breast cancer
  • post-partum breast engorgement
• both
  • LHRH deficiency
  • anemia
  • myotonia congenita

Dosage

• hypogonadism 5-20 mg PO QD
• inoperable breast cancer
  • 10-20 mg/day in divided doses
  • continue for 1 month for a subjective response
  • continue for 2-3 months for an objective response

Tabs: 2, 5, 10 mg.

Adverse effects

• common (> 10%)
  • edema, acne, breast soreness
• less common (1-10%)
  • GI irritation, nausea/vomiting, hepatic dysfunction, 3 uncommon (< 1%)
  • hepatic necrosis, leukopenia, hypercalcemia, polycythemia, cholestatic hepatitis, hypersensitivity
• males
  • gynecomastia
  • priapism
  • male pattern baldness
  • retention of water & electrolytes
  • suppression of clotting factors
  • prostatic hypertrophy & prostate carcinoma
  • impotence
  • testicular atrophy
• females
  • amenorrhea
  • deepining of the voice
  • clitoral enlargement
  • hirsutism

• drug adverse effects of androgens

Drug interactions

• fluoxymesterone increases anti-coagulant effect of warfarin
• cyclosporine

Mechanism of action

androgen

More general terms

• androgen or anabolic steroid

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6446
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3387